Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amneal Pharmaceuticals ( (AMRX) ) has provided an update.
Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026, where shareholders voted on director elections, executive compensation and the company’s auditor. All nominated directors, including Deb Autor, the Patel family members and other board members, were elected to serve until the 2027 Annual Meeting, reflecting strong investor support for the current board composition.
Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified Ernst & Young LLP as Amneal’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The broad approval of these proposals signals continued confidence in Amneal’s leadership, governance practices and financial oversight among its stockholder base.
The most recent analyst rating on (AMRX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
The score is driven primarily by improving financial fundamentals (notably cash generation and recent deleveraging) and a constructive earnings outlook with margin/EPS expansion. These positives are weighed down by a rich valuation (high P/E, no dividend) and only moderately supportive technicals, with corporate events adding modest net positivity but including settlement-related risk.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. is a pharmaceutical company that develops and manufactures prescription drugs. The company operates in the broader healthcare and life sciences industry, focusing on producing and supplying medications for patients and healthcare providers in its markets.
Average Trading Volume: 1,871,678
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.34B
Learn more about AMRX stock on TipRanks’ Stock Analysis page.